Pfizer To Present ALLHAT Analysis At Advisory Committee On Antihypertensive Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will present a non-inferiority analysis suggesting Norvasc (amlodipine) is similar to the diuretic chlorthalidone in preventing hypertension outcomes during a June 15 meeting of FDA's Cardiovascular & Renal Drugs Advisory Committee, the agency says.
You may also be interested in...
Antihypertensive Indications Should Include Benefit On Cardiac Outcomes, Cmte. Says
Most conclusive benefit seen from lowering blood pressure is reduction of stroke, Cardiovascular & Renal Drugs Advisory Committee says. Products that have cardiac outcomes studies could include data in labeling, committee adds.
Antihypertensive Indications Should Include Benefit On Cardiac Outcomes, Cmte. Says
Most conclusive benefit seen from lowering blood pressure is reduction of stroke, Cardiovascular & Renal Drugs Advisory Committee says. Products that have cardiac outcomes studies could include data in labeling, committee adds.
FDA Proposes Antihypertensive Class Indication For Reducing CV Events
Adding an indication for reducing cardiovascular adverse event risk is one option FDA will have its Cardiovascular & Renal Drugs Advisory Committee consider for antihypertensive class labeling June 15. Other class labeling options offered in FDA briefing document would amend the clinical trials section.